Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 20.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 502,083 shares of the medical research company's stock after acquiring an additional 84,710 shares during the period. Thermo Fisher Scientific comprises approximately 0.6% of Natixis Advisors LLC's holdings, making the stock its 24th largest position. Natixis Advisors LLC owned approximately 0.13% of Thermo Fisher Scientific worth $310,573,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in TMO. Signature Resources Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company's stock worth $25,000 after acquiring an additional 35 shares during the period. New Millennium Group LLC purchased a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $29,000. Stephens Consulting LLC boosted its stake in shares of Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company's stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth $32,000. Finally, Bank & Trust Co purchased a new position in Thermo Fisher Scientific during the second quarter valued at $33,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 3.7 %

Shares of NYSE:TMO traded down $19.94 during trading hours on Friday, hitting $513.08. 3,953,117 shares of the company's stock traded hands, compared to its average volume of 1,474,214. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The business has a fifty day moving average price of $586.43 and a 200-day moving average price of $582.24. Thermo Fisher Scientific Inc. has a 1 year low of $464.17 and a 1 year high of $627.88. The firm has a market capitalization of $196.25 billion, a P/E ratio of 32.17, a price-to-earnings-growth ratio of 3.58 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company's revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.69 earnings per share. Equities analysts expect that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.30%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific declared that its board has approved a stock buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board believes its shares are undervalued.

Analyst Ratings Changes

TMO has been the topic of a number of analyst reports. Bernstein Bank lifted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a research report on Tuesday, October 22nd. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. Raymond James raised their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an "outperform" rating in a report on Thursday, July 25th. UBS Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a research report on Monday, September 16th. Finally, Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $649.33.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares of the company's stock, valued at $67,175,513.68. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,150 shares of company stock worth $20,651,865. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.